This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.
Investigator's sites: 60 sites in Germany.
Primary objectives:
* Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. * Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS) * Documentation of treatment strategy
AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
Age ≥ 18 years. There is no upper age limit.
Signed written informed consent
there are no exclusion criteria